Home › Funds › Decheng Capital LLC › ACRS
Decheng Capital LLC position in ACRS
ACLARIS THERAPEUTICS INC · Health Care
Decheng Capital LLC reported holding 4,041,736 shares of ACRS (ACLARIS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$21.3M, representing 3.10% of its reported portfolio and ranking #3 among its reported holdings. Decheng Capital LLC has disclosed ACRS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Decheng Capital LLC's ACRS position evolved
Decheng Capital LLC first disclosed a stake in ACRS in Q4 2024 at 2,266,667 shares (US$5.6M). The position peaked in Q2 2026 at 4,041,736 shares, worth US$21.4M. Across 8 filings, Decheng Capital LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 4,041,736 shares valued at US$21.3M. Notable position changes include a 78% increase in Q1 2025 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.27M | $5.62M | New |
| Q1 2025 | 4.04M | $6.18M | Add |
| Q2 2025 | 4.04M | $5.74M | Hold |
| Q3 2025 | 4.04M | $7.68M | Hold |
| Q4 2025 | 4.04M | $12.17M | Hold |
| Q1 2026 | 4.04M | $15.16M | Hold |
| Q2 2026 | 4.04M | $21.38M | Hold |
| Q3 2026 | 4.04M | $21.26M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACRS and 13F data
ACRS (ACLARIS THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ACRS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.3M), BML Capital Management, LLC (US$57.6M), Deep Track Capital, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACRS
- RA CAPITAL MANAGEMENT, L.P. 12.72M sh · $67.30M · Q2 2026
- BML Capital Management, LLC 10.96M sh · $57.62M · Q3 2026
- Deep Track Capital, LP 9.35M sh · $49.44M · Q2 2026
- Vivo Capital, LLC 6.69M sh · $35.21M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.93M sh · $26.06M · Q2 2026
- Rock Springs Capital Management LP 4.33M sh · $22.91M · Q2 2026
- Jones Hill Capital LP 2.50M sh · $13.17M · Q3 2026
- Kalehua Capital Management LLC 1.83M sh · $9.64M · Q3 2026
- Palo Alto Investors LP 1.61M sh · $8.54M · Q2 2026
- MPM BioImpact LLC 1.04M sh · $5.51M · Q2 2026
- Aldebaran Capital, LLC 936.18K sh · $4.92M · Q3 2026
- Three Bridge Wealth Advisors, LLC 714.82K sh · $3.76M · Q3 2026
More on Decheng Capital LLC
FAQ
How long has Decheng Capital LLC held ACRS?
Decheng Capital LLC has disclosed ACRS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Decheng Capital LLC's current position in ACRS?
As of Q3 2026, Decheng Capital LLC holds 4.04M shares of ACRS (ACLARIS THERAPEUTICS INC), valued at $21.26M, representing 3.10% of its reported portfolio and ranking #3.
Has Decheng Capital LLC been buying or selling ACRS?
In the latest 13F filing (Q3 2026), Decheng Capital LLC held unchanged its position in ACRS. The position peaked in Q2 2026 at 4.04M shares.
Which other funds hold ACRS?
Other major institutional holders of ACRS include RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, Deep Track Capital, LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.